Literature DB >> 11034405

Granzyme activity in the inflamed lung is not controlled by endogenous serine proteinase inhibitors.

G M Tremblay1, A M Wolbink, Y Cormier, C E Hack.   

Abstract

Numerous lung diseases, such as hypersensitivity pneumonitis (HP), are characterized by the presence of activated alveolar CTL and NK cells. Since these cells produce granzymes, granzyme A and B levels in bronchoalveolar lavage (BAL) fluids from 14 normal subjects and 12 patients with HP were measured by ELISA. Median (range) BAL granzyme A and B levels were 4 (0-37) and 0 (0-6) pg/ml in normal subjects. BAL granzyme levels were significantly higher in HP patients, being at 74 (0-1,889) and 10 (0-78) pg/ml for granzymes A and B, respectively. In vitro, neither of the three main serine protease inhibitors of the lung, namely alpha1-antitrypsin, secretory leukocyte protease inhibitor, and elafin, showed any effect on granzyme A or B activity. In addition, granzyme A was shown to be fully active in BAL fluids. Hence, these data show that granzyme activity may be poorly controlled by protease inhibitors in inflamed tissues. Thus, granzymes could contribute to tissue remodeling and inflammation characterizing HP.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11034405     DOI: 10.4049/jimmunol.165.7.3966

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  Serine protease inhibition attenuates rIL-12-induced GZMA activity and proinflammatory events by modulating the Th2 profile from estrogen-treated mice.

Authors:  Ebru Karpuzoglu; Chad W Schmiedt; Julian Pardo; Megan Hansen; Tai L Guo; Steven D Holladay; Robert M Gogal
Journal:  Endocrinology       Date:  2014-05-19       Impact factor: 4.736

2.  Granzyme A and thrombin differentially promote the release of interleukin-8 from alveolar epithelial A549 cells.

Authors:  Yumiko Yoshikawa; Hirofumi Hirayasu; Satoshi Tsuzuki; Tohru Fushiki
Journal:  Cytotechnology       Date:  2010-04-28       Impact factor: 2.058

3.  Increase in granzyme B+ lymphocytes and soluble granzyme B in bronchoalveolar lavage of allergen challenged patients with atopic asthma.

Authors:  K Bratke; B Böttcher; K Leeder; S Schmidt; M Küpper; J C Virchow; W Luttmann
Journal:  Clin Exp Immunol       Date:  2004-06       Impact factor: 4.330

4.  Carrageenan inhibits granzyme A-induced detachment of and interleukin-8 release from alveolar epithelial A549 cells.

Authors:  Yumiko Yoshikawa; Hirofumi Hirayasu; Satoshi Tsuzuki; Tohru Fushiki
Journal:  Cytotechnology       Date:  2008-11-06       Impact factor: 2.058

5.  Perforin and granzyme B have separate and distinct roles during atherosclerotic plaque development in apolipoprotein E knockout mice.

Authors:  Paul R Hiebert; Wendy A Boivin; Hongyan Zhao; Bruce M McManus; David J Granville
Journal:  PLoS One       Date:  2013-10-24       Impact factor: 3.240

6.  RNA-Seq analysis of chikungunya virus infection and identification of granzyme A as a major promoter of arthritic inflammation.

Authors:  Jane A C Wilson; Natalie A Prow; Wayne A Schroder; Jonathan J Ellis; Helen E Cumming; Linden J Gearing; Yee Suan Poo; Adam Taylor; Paul J Hertzog; Francesca Di Giallonardo; Linda Hueston; Roger Le Grand; Bing Tang; Thuy T Le; Joy Gardner; Suresh Mahalingam; Pierre Roques; Phillip I Bird; Andreas Suhrbier
Journal:  PLoS Pathog       Date:  2017-02-16       Impact factor: 6.823

Review 7.  Modulation of Inflammation by Extracellular Granzyme A.

Authors:  Kim R van Daalen; Josephine F Reijneveld; Niels Bovenschen
Journal:  Front Immunol       Date:  2020-05-19       Impact factor: 7.561

8.  Natural killer cell NKG2D and granzyme B are critical for allergic pulmonary inflammation.

Authors:  Nazanin Farhadi; Laura Lambert; Chiara Triulzi; Peter J M Openshaw; Nadia Guerra; Fiona J Culley
Journal:  J Allergy Clin Immunol       Date:  2013-11-28       Impact factor: 10.793

Review 9.  Intracellular versus extracellular granzyme B in immunity and disease: challenging the dogma.

Authors:  Wendy Anne Boivin; Dawn Michelle Cooper; Paul Ryan Hiebert; David James Granville
Journal:  Lab Invest       Date:  2009-09-21       Impact factor: 5.502

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.